Abstract
Several tumors overexpress somatostatin receptors (SSTR) and can thus be imaged with radiolabeled analogues of somatostatin. Tc-99m depreotide is a new radiolabeled somatostatin analogue that shows high affinity for SSTR2, SSTR3, and SSTR5 subtypes. It has been recently FDA-approved for use in the evaluation of indeterminate solitary pulmonary nodules. SPECT with Tc-99m depreotide is highly accurate in this clinical setting and may be preferable to FDG-PET because of its lower cost and wider availability. Large studies are also underway to evaluate the accuracy of Tc-99m depreotide in staging of lung cancer. Copyright 2002, Elsevier Science (USA). All rights reserved.
Cite
CITATION STYLE
Menda, Y., & Kahn, D. (2002). Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide. Seminars in Nuclear Medicine, 32(2), 92–96. https://doi.org/10.1053/snuc.2002.31564
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.